| abstract |
The present invention provides a novel pharmaceutical composition comprising, as an active ingredient, a 4-phenylpinene derivative specific for a peripheral cannabinoid receptor. In particular, compounds of the present invention bind effectively to CB2 but do not bind to CB1. This compound shows no activity in behavioral tests in mice, which were also shown to be specific for CB1-mediated central nervous system tetrahydrocannabinol (THC) -type activity, but reduced blood pressure And block intestinal motility and exhibit anti-inflammatory and peripheral analgesic effects. The present invention also relates to a method for treating, preventing or managing hypertension, inflammation, pain, gastrointestinal diseases, autoimmune diseases and tumors with the compounds of the present invention. |